Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inaticabtagene autoleucel + Auto-HSCT in MRD+ B-ALL
NCT06608732Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inaticabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Relapse-Free Survival at 2 years. Started Aug 2024; status: recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06608732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608732.